

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/994,466	11/26/2001	Ragupathy Madiyalakan	AREX-P03-002	7223
28120 7	. 01/23/2006		EXAMINER	
FISH & NEAVE IP GROUP			HUFF, SHEEL	A JITENDRA
ROPES & GRAY LLP ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624		ART UNIT	PAPER NUMBER	
		1643		

DATE MAILED: 01/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/994,466	MADIYALAKAN, RAGUPATHY			
Office Action Summary	Examiner	Art Unit			
	Sheela J. Huff	1643			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status		,			
<ul> <li>1) ⊠ Responsive to communication(s) filed on <u>06 Description</u></li> <li>2a) ⊠ This action is <b>FINAL</b>. 2b) □ This</li> <li>3) □ Since this application is in condition for allowant closed in accordance with the practice under E</li> </ul>	action is non-final.  nce except for formal matters, pro				
Disposition of Claims	x parte Quayre, 1900 C.D. 11, 40	. O.G. 213.			
·		·•			
<ul> <li>4)  Claim(s) 1,2,5-11,16-18,21-23,25-29,42,43 and 4a) Of the above claim(s) is/are withdraw</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 1-2, 5-11, 16-18, 21-23, 25-29, 42-43</li> <li>7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or</li> </ul>	vn from consideration.  and 47 is/are rejected.	ion.			
Application Papers					
9) The specification is objected to by the Examine	Γ.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> </ol>	4) Interview Summary Paper No(s)/Mail Da	·			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date		atent Application (PTO-152)			

### **DETAILED ACTION**

## Response to Amendment

The amendment filed on 12/6/05 has been considered. Applicant's arguments are deemed to not be persuasive.

Claims 1-2, 5-11, 16-18, 21-23, 25-29, 42-43 and 47 are pending.

# Response to Arguments Claim Rejections - 35 USC § 112

Claims 1-2, 5-11, 16-18, 21-23, 25-29, 42-43 and 47 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The reasons for this rejection are of record in the paper mailed 6/6/05.

Applicant argues that the amendment overcomes the rejection. The amendment (specifically the terminology "the epitope comprising a peptide and a carbohydrate") still encompasses that the epitope be composed of both the peptide and the carbohydrate. Therefore the rejection still stands.

New Grounds of Rejection

Application/Control Number: 09/994,466

Art Unit: 1643

Claims 1-2, 5-11, 16-18, 21-23, 25-29, 42-43 and 47 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to the epitope comprising a peptide and a carbohydrate, wherein the peptide comprises the amino acid sequence DTRPAP (SEQ ID NO:5)". While the amino acid sequence of SEQ ID NO:5 is adequately described in the specification as-filed, thereby providing an adequate basis for the polypeptide of SEQ ID NO:5; there is insufficient written description as to the identity of a peptide comprising the amino acid sequence DTRPAP (SEQ ID NO:5) that would still maintain the function of the polypeptide. Consequently, the specification does not provide an adequate written description of a peptide comprising the amino acid sequence DTRPAP (SEQ ID NO:5).

The specification as filed does not provide adequate written description support for a peptide comprising the amino acid sequence DTRPAP (SEQ ID NO:5). This reads on peptides that have SEQ ID NO. 5 as part of the sequence with additional amino acids on either side of SEQ ID NO. 5. The additional amino acids can be of any composition or any length and applicant has not adequately defined what there are. Polypeptides having diverse functions are encompassed by the phrase. Thus a broad genus having potentially highly diverse functions is encompassed by the phrase and conception cannot be achieved until reduction to practice has occurred, regardless of

**Art Unit: 1643** 

the complexity or simplicity of the method. For example, Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000) teach that the skilled artisan is well aware that assigning functional activities for any particular protein or protein family based upon sequence homology is inaccurate, in part because of the multifunctional nature of proteins (e.g., Abstract≅and Sequence-based approaches to function prediction, page 34). Even in situations where there is some confidence of a similar overall structure between two proteins, only experimental research can confirm the artisan₃s best guess as to the function of the structurally related protein (see in particular Abstract and Box 2). Adequate written description requires more than a mere statement that it is part of the invention. The sequence itself is required. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016.

Therefore, only SEQ ID No. 5 meets the written description provision of 35 U.S.C. 112, first paragraph. <u>Vas-Cath Inc. v. Mahurkar</u>, 19 USPQ2d 1111, makes clear that Aapplicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the written description inquiry, whatever is now claimed. (See page 1117.) The specification does not clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed (See <u>Vas-Cath</u> at page 1116.). Consequently, Applicant was not in possession of the instant claimed invention. See <u>University of California v. Eli Lilly and Co.</u> 43 USPQ2d 1398.

Application/Control Number: 09/994,466

Art Unit: 1643

Applicant is directed to the Guidelines for the Examination of Patent Applications
Under the 35 U.S.C. 112, & 1 "Written Description" Requirement, Federal Register, Vol.
66, No. 4, pages 1099-1111, Friday January 5, 2001.

Claims 16-17, 21-23, 25-29 and 42 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 16, line 1, "the epitope" has improper antecedent basis.

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1643

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J. Huff whose telephone number is 571-272-0834. The examiner can normally be reached on Tuesdays and Thursdays from 5:30am to 2:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sheela J Huff Primary Examiner Art Unit 1643

sjh